FINEIMMU Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Guangzhou Guangdong China

Primary Industry

Biotechnology

About

Established in 2016 and based in Guangzhou, China, FINEIMMU is a biotechnology and pharmaceutical company that focuses on research and development of solid tumor immunotherapy drug. The company has a 1,600 square meter immunotherapy R&D laboratory and a GMP manufacturing plant for cell therapy products. The company completed a preclinical study of individualized TCR-T cell therapy in 2018. The company's R&D team has nearly 20 years of experience in tumor immunotherapy research and clinical application. In addition, the company has more than 20 immune cell therapy products or technologies in development as of 2022. The company's laboratory has many biotechnology platforms such as animal platform, antibody platform, small molecule drug platform, high throughput and single cell sequencing platform. The main research equipment includes mass spectrometer, small animal imager, flow cytometer, electron microscope, automatic gene sequencer, automatic biochemical analyzer, automatic enzyme marker, laser microdissection instrument, liquid flash instrument and ultracentrifuge. In additions, the company self-developed cell therapy drug products include individualized polyclonal TCR-T cell therapeutics, SUPER CAR (Chimeric Antigen Receptor)-T/TCR (T cell receptor)-T and genetically modified-free cell therapy products.

Current Investors

Panacea Venture, Huafang Capital, Beijing Yabao Investment Management

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.fineimmu.com

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.